Therapeutic Co-targeting of oxidative phosphorylation and pyrimidine synthesis restores gemcitabine response in pancreatic ductal adenocarcinoma
Translational Research · 2026
DOI: 10.1016/j.trsl.2026.09.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2026. Verfasst von Wenhui Ouyang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Deoxycytidine, Oxidative Phosphorylation, Pyrimidines, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Gemcitabine resistance remains a major barrier to effective therapy in pancreatic ductal adenocarcinoma (PDAC), and current combination regimens show potential to overcome this resistance. Here, we identify the mitochondrial ribosomal proteins MRPS22 and MRPL3 as key metabolic gatekeepers that maintain mitochondrial OXPHOS and pyrimidine metabolism, thereby promoting pancreatic cancer cell proliferation and chemoresistance. Across independent cohorts, high MRPS22/MRPL3 expression associates with poorer survival. Depletion of either gene in PDAC curtailed cell proliferation and xenograft growth, which might be due to an impaired mitochondria function, including destabilized respiratory super-complex assembly, diminished ATP production, and increased oxidative stress. Multi-omics profiling revealed a broad reduction of central-carbon intermediates and a pronounced blockade of de novo pyrimidine synthesis at the dihydroorotate dehydrogenase (DHODH) node. MRPS22 depletion hampered nucleotide-pool generation, and exogenous deoxynucleotides partially rescued PDAC cell growth when MRPs were knocked down. Pharmacologic OXPHOS inhibition increased gemcitabine sensitivity, whereas gemcitabine-resistant derivatives exhibited heightened OXPHOS activity and upregulated mitochondrial ribosomal programs. Co-targeting OXPHOS (antimycin A) or DHODH (brequinar) with gemcitabine produced Loewe synergy in vitro and suppressed growth of gemcitabine-resistant xenografts without affecting body weight. Collectively, these findings established MRPS22/MRPL3 as translation-level drivers of PDAC metabolic fitness and nominate OXPHOS/DHODH blockade as a rational combination strategy to overcome gemcitabine resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- School of Public Health, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Zhejiang Provincial Key Laboratory of Medical Genetics, College of Laboratory Medicine and Life sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China. Electronic address: shanying.gui@hmc.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ouyang, W., Wang, J., Chen, J., Fang, Z., Wei, T., Qian, J., & Gui, S. (2026). Therapeutic Co-targeting of oxidative phosphorylation and pyrimidine synthesis restores gemcitabine response in pancreatic ductal adenocarcinoma. Translational Research. https://doi.org/10.1016/j.trsl.2026.09.009
Vancouver
Ouyang W, Wang J, Chen J, Fang Z, Wei T, Qian J, et al. Therapeutic Co-targeting of oxidative phosphorylation and pyrimidine synthesis restores gemcitabine response in pancreatic ductal adenocarcinoma. Translational Research. 2026. doi:10.1016/j.trsl.2026.09.009
BibTeX
@article{Ouyang2026,
author = {Ouyang, Wenhui and Wang, Jie and Chen, Jie and Fang, Zemin and Wei, Ting and Qian, Jiazi and Gui, Shanying},
title = {Therapeutic Co-targeting of oxidative phosphorylation and pyrimidine synthesis restores gemcitabine response in pancreatic ductal adenocarcinoma},
journal = {Translational Research},
year = {2026},
doi = {10.1016/j.trsl.2026.09.009}
}
EUVIMED